Switch to: References

Add citations

You must login to add citations.
  1. Reasons Why Post-Trial Access to Trial Drugs Should, or Need not be Ensured to Research Participants: A Systematic Review.N. Sofaer & D. Strech - 2011 - Public Health Ethics 4 (2):160-184.
    Background : researchers and sponsors increasingly confront the issue of whether participants in a clinical trial should have post-trial access (PTA) to the trial drug. Legislation and guidelines are inconsistent, ambiguous or silent about many aspects of PTA. Recent research highlights the potential importance of systematic reviews (SRs) of reason-based literatures in informing decision-making in medicine, medical research and health policy. Purpose: to systematically review reasons why drug trial participants should, or need not be ensured PTA to the trial drug (...)
    Download  
     
    Export citation  
     
    Bookmark   31 citations  
  • Ancillary Care: From Theory to Practice in International Clinical Research.B. Pratt, D. Zion, K. M. Lwin, P. Y. Cheah, F. Nosten & B. Loff - 2013 - Public Health Ethics 6 (2):154-169.
    How international research might contribute to justice in global health has not been substantively addressed by bioethics. This article describes how the provision of ancillary care can link international clinical research to the reduction of global health disparities. It identifies the ancillary care obligations supported by a theory of global justice, showing that Jennifer Ruger’s health capability paradigm requires the delivery of ancillary care to trial participants for a limited subset of conditions that cause severe morbidity and mortality. Empirical research (...)
    Download  
     
    Export citation  
     
    Bookmark   7 citations  
  • Does Research Ethics Rest on a Mistake? The Common Good, Reasonable Risk and Social Justice.Alex John London - 2005 - American Journal of Bioethics 5 (1):37 – 39.
    Download  
     
    Export citation  
     
    Bookmark   10 citations